These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2964173)

  • 1. Physiology of normal and abnormal blinking.
    Karson CN
    Adv Neurol; 1988; 49():25-37. PubMed ID: 2964173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinking.
    Karson CN
    Bull Soc Belge Ophtalmol; 1989; 237():443-57. PubMed ID: 2486118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical physiology of dopa dyskinesia.
    Hallett M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
    Jutkiewicz EM; Bergman J
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys.
    Taylor JR; Elsworth JD; Lawrence MS; Sladek JR; Roth RH; Redmond DE
    Exp Neurol; 1999 Jul; 158(1):214-20. PubMed ID: 10448434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinking and tear break-up during four visual tasks.
    Himebaugh NL; Begley CG; Bradley A; Wilkinson JA
    Optom Vis Sci; 2009 Feb; 86(2):E106-14. PubMed ID: 19156014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blink rate in boys with fragile X syndrome: preliminary evidence for altered dopamine function.
    Roberts JE; Symons FJ; Johnson AM; Hatton DD; Boccia ML
    J Intellect Disabil Res; 2005 Sep; 49(Pt 9):647-56. PubMed ID: 16108982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity.
    van der Post J; de Waal PP; de Kam ML; Cohen AF; van Gerven JM
    J Psychopharmacol; 2004 Mar; 18(1):109-14. PubMed ID: 15107193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys.
    Kleven MS; Koek W
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1211-9. PubMed ID: 8968343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dopaminergic receptors: structural features and functional implications].
    Nieoullon A; Amalric M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S59-68. PubMed ID: 12690665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats.
    Desai RI; Neumeyer JL; Bergman J; Paronis CA
    Behav Pharmacol; 2007 Dec; 18(8):745-54. PubMed ID: 17989512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurochemistry of Parkinson's disease and parkinsonism plus].
    Pascual J; Misiego M
    Rev Neurol; 1997 Aug; 25 Suppl 2():S141-6. PubMed ID: 9280680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.